⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 30, 2024Open Access

Supplementary Figure 4 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

Benjamin Garmezy Mitesh J. Borad Rastilav Bahleda Cesar A. Perez Li‐Tzong Chen Shumei Kato Do‐Youn Oh Paul Severson Betty Y. Tam Cheng S. Quah James J. Harding

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplemental Figure 4 - Pharmacodynamic effect of KIN-3248 treatment was evaluated in serial sections of paired biopsy samples by measuring changes in phospho-ERK and DUSP6 gene expression.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Garmezy et al. (2024) studied this question.

synapsesocial.com/papers/68e6cd14b6db64358764b1fb https://doi.org/10.1158/2767-9764.25723490.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 4 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
2Supplementary Figure 3 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
3Supplementary Figure 3 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
4Supplementary Figure 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
5Supplementary Figure 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024

More related papers

FIGURE 3 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
Supplementary Figure 5 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
Supplementary Figure 5 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024